ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note released on Monday, Benzinga reports. Cantor Fitzgerald also issued estimates for ORIC Pharmaceuticals’ FY2024 earnings at ($1.82) EPS. Several other research analysts have also commented on the company. Wedbush reaffirmed an outperform rating and set a […]
More Stories
Trump Orders Navy to Replace Newer Fighter Launch System With Older Steam Catapults
By Timothy Frudd President Donald Trump ordered the Navy on Aug. 13 to return to using steam catapults to launch...
Trade Court Upholds Trump’s Shutdown of $800 De Minimis Duty Exemption
By Matthew Vadum The U.S. Court of International Trade on Aug. 13 upheld the Trump administration’s authority to end the...
Trump Says US Has ‘Total Control’ of Hormuz
By Tom Ozimek President Donald Trump said the United States has “total control” over the Strait of Hormuz, while Energy...
US Annual Inflation Rate Stabilizes in July, Slowing to 3.4 Percent
By Andrew Moran Stabilizing energy prices have helped cool off inflation pressures for the second straight month, new government data...
State Department Launches Birth Tourism Prevention Task Force
By Troy Myers The Department of State on Wednesday announced the existence of a task force that has already revoked...
Todd Blanche Sworn In as Attorney General
By Kimberly Hayek Todd Blanche, President Donald Trump’s former personal lawyer, was sworn in Monday as U.S. attorney general and...